Abstract
Introduction
Transcatheter aortic valve implantation (TAVI) is now a recognized therapy for patients with severe aortic stenosis with contraindications to surgery or ineligible for surgery because of the high risks associated with therapy. TAVI procedure reduces mortality in inoperable elderly patients compared with conservative treatment [1] . TAVI can achieve comparable or better results in terms of survival after treatment in elderly patients who require the procedure of surgical aortic valve replacement, but they are at their high risk related with this therapy as compared to surgical treatment [2, 3] .
In addition, the therapy is also expected to improve the quality of life, i.a. by improving the efficiency of the cardiovascular system. It may be difficult to achieve due to the elderly age of the patients and the presence of comorbidities. The efficiency of the cardiovascular system can be assessed on the basis of efficiency tests, such as an exercise test, spiroergometric test and simply performable 6-minute walk test (6MWT). This test is optimal to use in elderly patients with aortic stenosis, as it allows to estimate the capacity of the cardiovascular system and to evaluate the symptoms associated with aortic stenosis [4] [5] [6] [7] . There are few data in the literature on the 6MWT in patients undergoing TAVI [4] [5] [6] [7] . These data are insufficient because they are related to the population of patients at a very old age with many different comorbidities and they are usually short-term observations.
The aim of this study was to evaluate the efficiency of the cardiovascular system in patients before and 30 days after TAVI and at the 6-12-month follow-up based on the 6MWT.
Methods
From January 2009 to February 2012, in the Silesian Center for Heart Diseases in Zabrze, TAVI was performed in 104 patients. The patients were qualified for the treatment by the multidisciplinary team (Heart Team). Patients with severe symptomatic aortic stenosis, with a surface area of aortic valve in echocardiography (Echo) < 1 cm 2 , who were inoperable or for whom the risk of surgery by Logistic EuroScore was > 20% and/or by the Society of Thoracic Surgeons (STS) was > 10%, were qualified for the procedure. Of the 82 selected patients, 46 (56.1%) had Logistic EuroScore > 20%, and 8 (9.8%) had STS > 10%. Other patients with lower risk (Logistic EuroScore was < 20), but with comorbidities not covered in the scales of risk, however increasing the risk of surgical treatment (e.g. liver failure, porcelain aorta, the state after radiotherapy) were also qualified for TAVI. The lowest Logistic EuroScore was 1.5, the highest risk was 61.5%. The lowest risk assessed by the STS was 0.45, the highest risk by STS was 14.4%.
Among 36 (43.9%) patients with Logistic EuroScore < 20%: 10 (12.2%) patients had coronary artery bypass grafting with the opening of the chest. Twelve (14.6%) patients had porcelain aorta. Five (6.1%) patients had a surgical valve replacement procedure. Nine (11%) patients had multiple diseases not recognized in the scales of risk. The Heart Team decided to reject the surgery.
Out of 104 patients treated with TAVI, 82 patients underwent 6MWT before TAVI. The remaining 22 patients did not undergo 6MTW before TAVI for various reasons (patient's refusal, logistic problems, poor mobility, and other) ( Table 1) .
Only those patients (n = 82) who underwent 6MWT before TAVI were enrolled to prospective analysis (Fig. 1) .
Of the 82 patients who performed 6MWT before TAVI, 64 patients underwent 6MWT after TAVI in 30-day follow-up and 18 patients did not do 6MTW after TAVI in 30-day follow-up ( Fig. 2, Table 2 ).
Of the 82 patients who performed 6MWT before TAVI and in 30-day follow-up, 46 patients Table 1 . Six patients who did not undergo 6-minute walk test (6MWT) before transcatheter aortic valve implantation for logistic reasons. underwent 6MWT after TAVI in 6-12-month follow-up and 36 patients did not do 6MTW after TAVI in 6-12-month follow-up (Fig. 3) TAVI procedure was performed via the femoral artery in 50 (61.0%) patients, through the subclavian artery -in 17 (20.7%), through the ascending aorta -in 2 (2.4%), and through the apex of the heart -in 13 (15.9%) patients. The procedures were performed after the evaluation by the multidisciplinary team (Heart Team). The www.cardiologyjournal.org patients expressed their informed consent to the proposed treatment. The procedures were performed in the catheterization laboratory or in the hybrid operating theatre. Procedures performed transapically, transaortically, through subclavian artery and part of the procedures via the femoral artery were performed under general anesthesia and with the surgical exposing of the access site. Other procedures via the femoral artery were performed in deep sedation, percutaneously, under local anesthesia using vascular closers (Prostar, Proglide).
Before implantation, balloon aortic valvuloplasty was performed while pacing the right ventricle. Edwards-SAPIEN valve sizes of 23, 25 and 29, and CoreValve valve sizes of 26, 29, 31 were implanted. The procedures were carried out routinely, as described in previous publications [8] [9] [10] . The 6MWT was performed according to the standard procedure in accordance with the guidelines of the American Thoracic Society [11] , within a month before TAVI, up to a month after TAVI, and at the 6-12-month follow-up. In patients with New York Heart Association (NYHA) class IV, 6MWT was not performed. The patients had to bestride a 30-m hospital corridor. The subjects were encouraged to pass the largest distance in 6 min at their own pace. Before and after the 6MWT blood pressure, heart rate and oxygen saturation were recorded. The distance covered by the patient, the cause of the end of the test, if it was finished ahead of 6 min time, and symptoms occurring during exercise were registered. At the end of the test, dyspnea level was determined using a modified Borg scale [12] [13] [14] . Before TAVI and during the follow-up appointments, the degree of efficiency of the cardiovascular system according to the NYHA scale was determined. Before, after TAVI, and during the follow-up appointments, an experienced cardiologist performed the echocardiogram with Philips iE 33 xMATRIX and GE Vivid E9 device.
Statistical analysis
The received figures were expressed as mean ± standard deviation. In order to examine the compatibility of distributions with the normal distribution Kolmogorov-Smirnov test was used. If the distributions of the two variables in a pair were consistent with the normal one, T-test was used, and if the result was significant, error bars chart was made (mean and 95% confidence interval). If at least one of the distributions of variables in a pair differed significantly from the normal one, the Wilcoxon test was used, and if the test showed significant differences, a box chart was made (with marked quartiles and the typical area). To test changes in ordinal variables pairs, Wilcoxon test was used, and to test changes in nominal variables pairs -a sign test was used and frequency tables were made. The level of statistical significance was set at p < 0.05. The calculations were performed using IBM SPSS 22.0 software.
Results
Patient characteristics are shown in Table 3 . The results of the 6MWT are given in Table 4 .
In the 6MWT performed 30 days after TAVI, the distance did not increase in 21 (32.8%) patients, while in the 6MWT made 6-12 months after the TAVI, the distance did not increase in 12 (26.1%) patients.
Rating of the capacity of the cardiovascular system according to the NYHA scale
Before TAVI, out of 82 patients, 1 (1.2%) was in NYHA class I, 34 (41.5%) -in class II, and 47 (57.3%) -in class III. Thirty days after TAVI, 8 (11.9%) patients were in NYHA class I, 46 (68.7%) -class II, 10 (14.9%) -in class III, and 3 (4.5%) -in NYHA class IV. Before TAVI, cardiovascular fitness according to NYHA averaged 2.54 ± 0.53, and 30 days after TAVI -2.12 ± 0.66. There was a significant decrease in the NYHA class range immediately after the procedure (p < 0.0001). In the 6-12-month follow-up, 14 (30.4%) patients were in NYHA class I, 29 (63.0%) -class II, and 3 (6.5%) -class III. In the 6-12-month follow-up after the TAVI, cardiovascular fitness according to NYHA averaged 1.76 ± 0.57. In the medium-term follow-up, a significant decrease in the NYHA class (p < 0.0001) was noted.
During 30-day follow-up, 43 (67.2%) patients had improvement in efficiency of the cardiovascular system. Distance amounted to 309.2 ± 84.9 m, 
m (p = NS).
During the 6-12-month follow-up, 34 (73.9%) patients had improvement in efficiency of the cardiovascular system. Distance among them was 360 ± 102.8 m, before TAVI it was 254.1 ± 88.7 m (p < 0.0001). Twelve (26.1%) patients did not achieve better results during the 6MWT. Distance among them was 295.4 ± 56.7 m, prior to TAVI it was 338.2 ± 80.5 m (p = NS).
Of the patients in NYHA class IV before TAVI, 5 (55.6%) patients finished 6MWT during the 30-day follow-up, and 5 (55.6%) patients finished 6MWT during the 6-12-month follow-up (Fig. 1 , Table 5 ).
Cardiovascular performance and physical fitness after TAVI are displayed in Table 6 . 2 ] increased (0.7 ± 0.3 before TAVI to 1.7 ± 0.6 in 30-day follow-up, p < 0.0001). Index of the aortic valve surface area [cm 2 /m 2 ] increased (0.3 ± ± 0.1 before TAVI to 0.9 ± 0.3 in 30-day follow--up, p < 0.0001). The average gradient through the aortic valve [mm Hg] decreased (53.3 ± 17.8 before TAVI to 9.2 ± 6.1 in 30-day follow-up, p < 0.0001).
During the 6-12-month follow-up, in 46 (56.1%) patients, echocardiographic parameters of the aortic valve improved. Left ventricular ejection fraction [%] did not change (48.3 ± 9.8 before TAVI to 49.5 ± 11.0 in 6-12-month follow-up, p = NS). 2 ] increased (0.7 ± ± 0.3 before TAVI to 1.7 ± 0.5 in 6-12-month follow-up, p < 0.0001). Index of the aortic valve surface area [cm 2 /m 2 ] increased (0.4 ± 0.2 before TAVI to 0.9 ± 0.3 in 6-12-month follow-up, p < 0.0001). The average gradient through the aortic valve [mm Hg] decreased (51.6 ± 16.6 before TAVI to 9.0 ± 4.0 in 6-12 month follow-up, p < 0.0001).
Discussion
As a result of TAVI, hemodynamic parameters of aortic failure, such as a reduction in average gradient and an increase in aortic valve surface area, were improved. The hemodynamic failure parameters improvement reached immediately after the surgery remained on the same level creating conditions to improve exercise tolerance evaluated in the 6MWT, and to improve the efficiency of the cardiovascular system, evaluated according to the NYHA classification. Many studies evaluating the results of TAVI showed remarkable improvement in the echocardiography parameters of aortic failure and in the capacity of the cardiovascular system, evaluated according to NYHA classification [1, 2, 4] .
The 6MWT is easy to perform, does not require any professional equipment, and can determine the overall exercise capacity of patients [11] . Exercise tolerance depends on the function of many systems, including the cardiovascular system. The 6MWT is used to assess exercise tolerance in patients with various diseases of the respiratory and cardiovascular system. It is also carried out before and after an appropriate method of treatment to evaluate its efficacy in various diseases of respiratory and cardiovascular systems [11] . It can be safely performed in older patients with heart failure and cardiomyopathies [11, 12, 14] .
In their study, Gotzmann et al. [4] evaluated 44 patients after implantation of aortic CoreValve by TAVI method. The patients, 30 days after TAVI, covered significantly longer distance when compared to the 6MWT test taken before TAVI (204 ± ± 103 m vs. 266 ± 123 m, p < 0.001) [4] . Bagur et al. [5] evaluated the usefulness of the 6MWT in 64 patients who underwent TAVI. Six months after TAVI they achieved a significant increase in the distance covered during the test (165.3 ± 79.7 m before TAVI to 231.7 ± 88.9 m 6 months after TAVI, p < 0.0001).
The authors of this study noted that there are about 25% patients out of the study group, in whom there was no growth or even a decline in the dis- Table 6 . Cardiovascular performance and physical fitness after transcatheter aortic valve implantation (TAVI). tance achieved in the 6MWT. Kleczyński et al. [7] evaluated 40 patients after the TAVI. After 12 months, they reported the largest increase in the walking distance in the 6MWT. It went up from 200 m before treatment to 325 m 12 months after TAVI. In the present study, 82 patients who underwent 6MWT prior to surgery and 6-12 months after surgery were evaluated. Not only the length of distance, but also various parameters of the effort test were rated, finding out that most of them improved after TAVI procedure. In this study, the distance in long-term follow-up increased from 276.1 ± 93.5 m before the surgery to 343.1 ± 96.7 m after the surgery (p < 0.0001). Initially, it was the longest distance observed in patients before TAVI and these patients achieved the longest distance after the surgery in the 6-12-month follow-up. These differences may be due to the characteristics of the group of people eligible for TAVI, age, comorbidities, as well as the fact that the 6MWT was not carried out among the most seriously ill (NYHA IV e.g.).
30-day follow-up
The PARTNER study showed comparable survival in patients after TAVI and patients after cardiac surgical treatment, and the study of Adams et al. [3] showed improvement in survival in the group treated by TAVI [2] . In addition to the observed improved survival, some studies also reported the improvement in life quality compared with the cardiac surgical therapy [7] . Life quality improvement can be also assessed indirectly through the 6MWT, which is an objective test reflecting everyday life activity. In the present study, no improvement in the 6MWT was observed in 32.8% of patients after 30 days, and after 6-12 months, still no improvement was noted in 23% of patients. Similar observations were made by Bagur et al. [5] who found out that as many as 1/4 of patients in the 6MWT did not improve or even deteriorated. It can be assumed that elderly patients and patients with comorbidities do not fully benefit immediately after the surgery. However, in the further period, still a large group of patients do not show any improvement in the 6MWT.
Moreover, there is a certain disproportion between the improvement in terms of the capacity of the cardiovascular system according to NYHA classification (approximate scale and difficult to assess in the elderly) and the fact that many patients reached no improvement in the 6MWT. This may result from qualifying for TAVI patients with severe stenosis of the aortic valve, and from the deterioration in exercise tolerance as the main symptom. It is very difficult to determine in elderly patients, whether this symptom is closely associated with aortic stenosis. This may depend on other comorbidities, therefore no improvement is observed in some patients after properly conducted TAVI procedure.
The fact that a certain group of patients do not improve their condition may depend, as previously noted, on the comorbidities, such as the severity of coronary artery disease, incomplete revascularization before TAVI, cardiomyopathies, mitral insufficiency, pulmonary hypertension, chronic obstructive pulmonary disease or common, at the older age, anemia and orthopedic problems.
Limitations of the study
The study was conducted in one center and included a small number of patients. Many patients could not arrive to participate in the study for logistic reasons.
Conclusions
1. After TAVI, a significant improvement in the 6MWT distance was achieved in the 30-day follow-up and even greater improvements in the later period (6-12 months). 2. An improvement was reported in various parameters of the 6MWT in the 30-day follow-up -a higher pulse rate before and after the test, higher systolic blood pressure after the test, smaller value in the Borg scale and lower incidence of chest pain and breathlessness and dyspnea/fatigue after the test. 3. The 6-12-month follow-up showed significant improvements in individual parameters of the 6MWT -higher pulse rate after the test, higher systolic and diastolic blood pressure before and after the test, and a lower incidence of chest pain. There was no improvement in the assessment of dyspnea according to the modified Borg scale and a significant reduction in dyspnea/fatigue after the 6MWT. 4. There was a significant improvement in efficiency of the cardiovascular system evaluated according to NYHA classification after the TAVI in the 30-day and the 6-12-month follow-ups. 5. After TAVI, a significant improvement in echocardiographic parameters of aortic valve failure was recorded. During 30-day followup and the 6-12-month follow-up increased: aortic valve surface area, index of the aortic valve surface area, and decreases the average gradient through the aortic valve.
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